What are the potential reversal strategies for newer anticoagulants in the setting of ICH?
Potential reversal strategies for newer anticoagulants in the setting of ICH include the use of FEIBA, other PCCs, or rFVIIa. FFP is of unclear utility, and vitamin K is not useful. It has been suggested that FEIBA or rFVIIa may be better for the direct thrombin inhibitor dabigatran, whereas other PCCs may be better for the factor Xa inhibitors rivaroxaban and apixaban, although these data are preliminary.